Mitsubishi Tanabe Pharma Corporation

Hidekazu Tsujishima

Ritsuo Imashiro

Norimitsu Hayashi

Osamu Sakurai

Kenji Morokuma

Hiroaki Sawamoto

Kunio Saruta

Hiroaki Shitama

Takashi Goi

Atsushi Sato

Yasuo Yamamoto

Tetsu Nakane

Kouichi Tanimoto

Chihiro Toshikawa

The present invention relates to a novel imidazole compound or a pharmaceutically acceptable salt thereof having a melanocortin receptor agonistic activity, and medical use thereof. The present invention relates to an imidazole compound represented by general formula [I] [wherein: Ring A represents an optionally substituted aryl group or the like; Rrepresents a hydrogen atom, an optionally substituted alkyl group, or the like; Rrepresents a hydrogen atom, a halogen atom, or the like; and Rrepresents an optionally substituted alkyl group] or a pharmaceutically acceptable salt thereof.

Substituted imidazoles as melanocortin receptor agonists

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof. 

Continuous arycyclic compound

Growing community of inventors

Osaka, Japan

Hidekazu Tsujishima